文献速递心力衰竭与心肌病

射血分数保留心衰的遗传病因:新兴药物治疗

Genetic causes of heart failure with preserved ejection fraction: emerging pharmacological treatments.
PubMed 文献 · Eur Heart J · 2023-01-01

本文综述射血分数保留心衰(HFpEF)中由遗传决定的特定心肌病亚群,包括肥厚型心肌病、心脏淀粉样变和贮积病,讨论现有及在研靶向治疗对这些患者管理的影响,并指出及时识别遗传病因对临床实践和试验设计的重要意义。

要点

  • HFpEF中存在由特定遗传性心肌病构成的亚群,需及时识别以启用疾病特异治疗。
  • 肥厚型心肌病、心脏淀粉样变和贮积病已有或正在开发靶向药物。
  • 这些患者对标准心衰治疗反应通常有限,纳入试验可能稀释主流HFpEF治疗疗效。

核心结论

  • 遗传性心肌病是HFpEF中一个值得关注的重要亚群,靶向治疗可显著改变患者生活质量和结局。
  • 对单基因心肌病分子机制的理解有助于识别治疗靶点并开发更广泛HFpEF表型的创新疗法。

研究设计与样本

  • 综述文章,总结遗传性心肌病所致HFpEF的现有及在研治疗。

主要发现

  • HFpEF由心脏重构、外周循环及年龄、高血压、肥胖、糖尿病等合并症复杂交互所致。
  • 部分HFpEF由遗传决定的特定心肌病引起,具有独特病理生理且日益可及靶向创新治疗。
  • 这些遗传病因虽各自罕见,但 collectively 构成HFpEF队列中一个相关亚群。
  • 这些患者对标准心衰治疗反应通常有限,纳入注册和试验可能稀释主流HFpEF治疗 perceived 疗效。

临床怎么用

  • 对HFpEF患者应警惕遗传性心肌病可能,及时识别以获取疾病特异治疗。
  • 在HFpEF试验和注册中需考虑遗传病因亚群,避免稀释主流治疗疗效评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heart failure with preserved ejection fraction (HFpEF) is a major driver of cardiac morbidity and mortality in developed countries, due to ageing populations and the increasing prevalence of comorbidities. While heart failure with reduced ejection fraction is dominated by left ventricular impairment, HFpEF results from a complex interplay of cardiac remodelling, peripheral circulation, and concomitant features including age, hypertension, obesity, and diabetes. In an important subset, however, HFpEF is subtended by specific diseases of the myocardium that are genetically determined, have distinct pathophysiology, and are increasingly amenable to targeted, innovative treatments. While each of these conditions is rare, they collectively represent a relevant subset within HFpEF cohorts, and their prompt recognition has major consequences for clinical practice, as access to dedicated, disease-specific treatments may radically change the quality of life and outcome. Furthermore, response to standard heart failure treatment will generally be modest for these individuals, whose inclusion in registries and trials may dilute the perceived efficacy of treatments targeting mainstream HFpEF. Finally, a better understanding of the molecular underpinnings of monogenic myocardial disease may help identify therapeutic targets and develop innovative treatments for selected HFpEF phenotypes of broader epidemiological relevance. The field of genetic cardiomyopathies is undergoing rapid transformation due to recent, groundbreaking advances in drug development, and deserves greater awareness within the heart failure community. The present review addressed existing and developing therapies for genetic causes of HFpEF, including hypertrophic cardiomyopathy, cardiac amyloidosis, and storage diseases, discussing their potential impact on management and their broader implications for our understanding of HFpEF at large.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Olivotto, Udelson, Pieroni, et al. Genetic causes of heart failure with preserved ejection fraction: emerging pharmacological treatments. Eur Heart J. 2023. PMID: 36582184. doi:10.1093/eurheartj/ehac764

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。